rs80338789
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PP3_StrongPP5_Very_Strong
The NM_000334.4(SCN4A):c.3395G>A(p.Arg1132Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000372 in 1,613,408 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000334.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152106Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461302Hom.: 0 Cov.: 36 AF XY: 0.00000138 AC XY: 1AN XY: 726946
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152106Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74310
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Sep 01, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 09, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 26, 2022 | Observed in the heterozygous state in individuals with hypokalemic periodic paralysis in the literature and not observed in controls (Arzel-Hezode et al., 2010; Matthews et al., 2009; Maggi et al., 2020); Observed in apparent homozygous state in one individual, with hypokalemic periodic paralysis; clinical and EMG phenotypes were more severe in the one homozygote than in heterozygotes (Arzel-Hezode et al., 2010); Published functional studies demonstrate this variant leads to abnormal depolarization of the sodium channel at resting potential leading to muscle hypo-excitability; It also alters channel activation and deactivation (Carle et al., 2006; Francis et al., 2011; Mnnikk et al., 2018); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21044565, 31567646, 21468196, 29606556, 23019082, 21490317, 20522878, 21841462, 16890191, 19882638, 31589614, 34608571, 29636418, 32849172, 19118277) - |
Hypokalemic periodic paralysis, type 2 Pathogenic:2Other:1
Pathogenic, no assertion criteria provided | literature only | OMIM | May 10, 2011 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Jan 17, 2022 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 20, 2020 | Variant summary: SCN4A c.3395G>A (p.Arg1132Gln) results in a conservative amino acid change located in the Ion transport domain (IPR005821) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 249412 control chromosomes (gnomAD). c.3395G>A has been reported in the literature in multiple individuals including one homozygote affected with SCN4A-Related Disorders (Carle_2006, Matthews_2009, Arzel-Hezode_2010). These data indicate that the variant is very likely to be associated with disease. At least two functional studies report this variant conducts an anomalous gating pore current (Carle_2006, Francis_2011). Two ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Hyperkalemic periodic paralysis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 22, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1132 of the SCN4A protein (p.Arg1132Gln). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects SCN4A function (PMID: 16890191, 21490317). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SCN4A protein function. ClinVar contains an entry for this variant (Variation ID: 21155). This missense change has been observed in individuals with autosomal dominant hypokalemic periodic paralysis (PMID: 16890191, 19118277, 19882638). It has also been observed to segregate with disease in related individuals. This variant is present in population databases (rs80338789, gnomAD 0.007%). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at